Therapy development in Huntington disease: From current strategies to emerging opportunities. (Q53716390)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

review article

1 reference

title

Therapy development in Huntington disease: From current strategies to emerging opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Albert R La Spada

1 reference

PubMed publication ID

29218782

18 May 2018

http://europepmc.org/abstract/MED/29218782

language of work or name

English

0 references

publication date

8 December 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medical Genetics

6 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

volume

176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

page(s)

842-861

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

6 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Baclofen and lithium in Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Serum haloperidol concentration and choreiform movements in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Results of the citalopram to enhance cognition in Huntington disease trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Earliest functional declines in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The effects of modafinil on mood and cognition in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Mirtazapine in suicidal Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

High-dose olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Pharmacological management of Huntington's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Direct and indirect pathways of basal ganglia: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The role of dopamine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Weight gain and ghrelin level after olanzapine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Functional anatomy of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A pilot study using nabilone for symptomatic treatment in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Effectiveness of risperidone in Huntington chorea patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Off label use of lithium in the treatment of Huntington's disease: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington disease: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

BMP responsiveness in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Nuclear Receptors, RXR, and the Big Bang

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Donepezil for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Treatment of depression in Huntington's disease with monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Pridopidine activates neuroprotective pathways impaired in Huntington Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

AMDIS Case Conference: Intrusive Medication Safety Alerts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Improvement of Huntington's disease with olanzapine and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The CREST-E study of creatine for Huntington disease: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's disease: from pathology and genetics to potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The gait abnormality of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Repeat expansion disease: progress and puzzles in disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's disease: underlying molecular mechanisms and emerging concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Sleep deficits but no metabolic deficits in premanifest Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A 5-year follow-up of deep brain stimulation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

"Huntingtin holiday": progress toward an antisense therapy for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Genome-editing Technologies for Gene and Cell Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Oligonucleotide-based therapy for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Silencing human genetic diseases with oligonucleotide-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Molecular biology of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Unintended effects of orphan product designation for rare neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Genetic testing of children at risk for Huntington's disease. US Huntington Disease Genetic Testing Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cerebral cortex structure in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cognitive Impairment in Huntington Disease: Diagnosis and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

The endocannabinoid system in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A Europe-wide assessment of current medication choices in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Patient and caregiver quality of life in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Diagnostic criteria for Huntington's disease based on natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Differential loss of striatal projection neurons in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Tiapride in the treatment of Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington disease: natural history, biomarkers and prospects for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's Disease and Dentatorubral‐Pallidoluysian Atrophy: Proteins, Pathogenesis and Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Increased rate of suicide among patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Dopamine and Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Therapeutic advances in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Lamotrigine in motor and mood symptoms of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Neurocognitive signs in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Role of brain-derived neurotrophic factor in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.38494

Cognitive function in early clinical phase huntington disease after rivastigmine treatment

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Psychopathology in Verified Huntington's Disease Gene Carriers

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Nabilone could treat chorea and irritability in Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Brain imaging and cognitive dysfunctions in Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Therapeutic effects of cystamine in a murine model of Huntington's disease.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Short-term effects of olanzapine in Huntington disease.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Microcircuitry of the direct and indirect pathways of the basal ganglia

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Clinical evaluation of amantadine and haloperidol in Huntington's chorea

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

A quantitative evaluation of the effect of diazepam in Huntington's chorea

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Treatment of Huntington's disease with clonazepam.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Adverse behavioral effects of amantadine therapy in Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Neuropathological classification of Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Effects of terguride in patients with Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl)

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Lioresal in Huntington's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Clonazepam in the treatment of choreiform activity

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975251

Extrapyramidal symptoms in neuroleptic recipients

2 November 2018

1 reference

12 December 2020

L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia

1 reference

12 December 2020

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

1 reference

12 December 2020

Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group

1 reference

12 December 2020

Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray

1 reference

12 December 2020

Single-stranded siRNAs activate RNAi in animals

1 reference

12 December 2020

Identifiers

DOI

10.1002/AJMG.A.38494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

PubMed publication ID

29218782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218782%20AND%20SRC:MED&resulttype=core&format=json